Skip to main content
SpringerLink
Log in

Alemtuzumab

Fatal immunocompromised infections and Epstein-Barr virus positive large B-cell lymphoma (first report of campylobacter and enterovirus infections): case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Roch N, Salameire D, Courby S, Orsini-Piocelle F, Pegourie-Bandelier B, Gressin R, Dumontet C, Sturm N, Berger F, Toffart A, Guellerin J, Gereige G, Hincky V, Epaulard O, Brion J, Pavese P, Larrat S, Morand P, Stahl J.Fatal viral opportunistic infections and Epstein-Barr virus positive large B-cell lymphoma after alemtuzumab treatment for a refractory Sezary syndrome. 17th European Congress of Clinical Microbiology and Infectious Diseases and the 25th International Congress of Chemotherapy: (plus poster) abstr. P640, 31 Mar 2007. Available from: URL: http://www.eccmid-icc.org - France

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Alemtuzumab. React. Wkly. 1150, 6 (2007). https://doi.org/10.1007/BF03272454

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03272454

Keywords

Search

Navigation